Pelage Pharmaceuticals (Pelage) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutic based on breakthrough discoveries to activate hair growth through a mechanism that targets the metabolism of hair follicle stem cells. The product is currently being clinically tested for all genders, skin types, and hair types.
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.
Iantrek, Inc. is an ophthalmic medical device company developing advanced micro-interventional surgical technologies. The CycloPen™ micro-interventional system targets the suprachoroidal outflow pathway – an established therapeutic target where MIGS micro-stent interventions have demonstrated significant and sustained outflow enhancement with the majority of patients achieving IOP reduction of 20% or more.
Aurion Biotech is a clinical-stage biotech company whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. Its first product candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care.
Sydnexis is a San Diego based clinical stage pharmaceutical company currently in the middle of a pivotal Phase 3 study, focused on the development of a novel proprietary formulation of low dose atropine for the treatment of myopia. Myopia is a growing public health challenge worldwide that’s expected to affect 5 billion people by the year 2050.
Re-Vana Therapeutics is developing sustained release ophthalmic therapeutics that can reduce the frequency of intravitreal injections required to treat a wide range of retinal diseases, including neovascular age-related macular degeneration. The Re-Vana platform has the potential to deliver at least 4 to 6 months sustained delivery of a large molecule biologic, including anti-VEGF therapies. Re-Vana’s technology could spur a new generation of glaucoma medications that may reduce or eliminate the need for eye drops by delivering small molecules for 6 to 9 months or longer.
Tarsus is a late clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions where there are limited treatment alternatives, starting with Demodex blepharitis. Tarsus is developing a pipeline of products, with the lead candidate, TP-03, in clinical development to treat Demodex blepharitis. TP-03 is a novel, topical ophthalmic drug that specifically targets the Demodex mite’s nervous system, thereby treating the underlying cause of disease.
TearClear is an emerging global ophthalmic pharmaceutical company focused on disrupting the way current topical medications are delivered to the ocular surface. The company’s first in class pharmaceutical platform ensures patient safety and compliance by capturing preservatives prior to administration on to the ocular surface. TearClear’s lead candidates in glaucoma will pave the way for future indications across multiple programs in development.
Tear Film Innovation’s iLux treats Meibomian Gland Dysfunction by the application of light-based heat and compression under direct visualization.
Surface Pharmaceuticals’ branded drug candidates are being developed to address targeted segments of the Dry Eye Disease (DED) market.
